Repairing Cells and Longevity Myths with Dr. Charles Brenner

Repairing Cells and Longevity Myths with Dr. Charles Brenner

Charles Brenner, a leading biochemist at City of Hope National Medical Center in L.A., discovered a vitamin precursor called NR that seems to enable repair of cellular damage that happens as we get older.

Charles Brenner

Meet Charles Brenner, the Longevity Skeptic. Brenner, a leading biochemist at City of Hope National Medical Center in L.A., has been attending the largest longevity conferences with one main purpose: to point out that some of the other speakers are full of it.

Brenner is "throwing cold water" on several scientists in the field of aging, accusing them of hyping various fountains of youth, despite limited evidence for these therapies.

In this podcast episode, Brenner sat down with Leaps.org to discuss his groundbreaking work on metabolism and his efforts to counter what he considers to be bad science.




Listen on Apple | Listen on Spotify | Listen on Stitcher | Listen on Amazon | Listen on Google


In addition to bringing his candor to conferences, Brenner is applying it in academic journals, publishing a paper in September, "A Science-Based Review of the World's Best-Selling Book on Aging," in which he pans the author of this bestseller, David Sinclair, a Harvard biologist, for talking up the potential for humans to live far past 100. These aspirations may sound nice, but they're not backed by science, Brenner says. He's had high-profile debates online with Sinclair and Aubrey de Grey, a prominent biomedical gerontologist.

Meanwhile, in his own lab work, Brenner is credited with identifying a vitamin precursor called NR that seems to enable repair of cellular damage that happens as we get older - a major discovery that he's helped turn into a supplement, commercialized with a company called ChromaDex.

Whether it's possible to extend human lifespan is a pressing question as investments in longevity startups are projected to increase from $40 billion to $600 billion over the next three years. The field of biological aging seems split on the question of whether "anti-aging" therapies can significantly lengthen our natural lifespans, as Sinclair believes. Brenner, Morgan Levine of Altos Labs and Matt Kaeberlein of the University of Washington have argued that the only realistic goal is to extend one's window of healthy years, or healthspan, rather than trying to break the biological ceiling of our species.

Brenner is an intriguing figure in these debates. Although he’s been introduced in public appearances as a longevity skeptic, he calls himself an optimist.

Links:
Charles Brenner, City of Hope

Charles Brenner Lab

Charles Brenner on Twitter

Charles Brenner's debate with Aubrey de Grey

Brenner's paper, "A Science-Based Review of the World's Best-Selling Book on Aging"

Peter Attia's recent blog on NR supplements

Brad Stanfield's recent reaction to "David Sinclair vs Charles Brenner"

ChromaDex NR supplement

Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.
Researchers advance drugs that treat pain without addiction

New therapies are using creative approaches that target the body’s sensory neurons, which send pain signals to the brain.

Neurocarrus

Opioids are one of the most common ways to treat pain. They can be effective but are also highly addictive, an issue that has fueled the ongoing opioid crisis. In 2020, an estimated 2.3 million Americans were dependent on prescription opioids.

Opioids bind to receptors at the end of nerve cells in the brain and body to prevent pain signals. In the process, they trigger endorphins, so the brain constantly craves more. There is a huge risk of addiction in patients using opioids for chronic long-term pain. Even patients using the drugs for acute short-term pain can become dependent on them.

Scientists have been looking for non-addictive drugs to target pain for over 30 years, but their attempts have been largely ineffective. “We desperately need alternatives for pain management,” says Stephen E. Nadeau, a professor of neurology at the University of Florida.

A “dimmer switch” for pain

Paul Blum is a professor of biological sciences at the University of Nebraska. He and his team at Neurocarrus have created a drug called N-001 for acute short-term pain. N-001 is made up of specially engineered bacterial proteins that target the body’s sensory neurons, which send pain signals to the brain. The proteins in N-001 turn down pain signals, but they’re too large to cross the blood-brain barrier, so they don’t trigger the release of endorphins. There is no chance of addiction.

Keep Reading Keep Reading
Sarah Philip
Sarah Philip is a London-based freelance journalist who writes about science, film and TV. You can follow her on Twitter @sarahph1lip.
Our devices are changing us

Tech-related injuries are becoming more common as many people depend on - and often develop addictions for - smart phones and computers.

In the 1990s, a mysterious virus spread throughout the Massachusetts Institute of Technology Artificial Intelligence Lab—or that’s what the scientists who worked there thought. More of them rubbed their aching forearms and massaged their cricked necks as new computers were introduced to the AI Lab on a floor-by-floor basis. They realized their musculoskeletal issues coincided with the arrival of these new computers—some of which were mounted high up on lab benches in awkward positions—and the hours spent typing on them.

Today, these injuries have become more common in a society awash with smart devices, sleek computers, and other gadgets. And we don’t just get hurt from typing on desktop computers; we’re massaging our sore wrists from hours of texting and Facetiming on phones, especially as they get bigger in size.

Keep Reading Keep Reading
Hanna Webster
Hanna Webster is a freelance science writer based in San Diego, California. She received a Bachelor’s degree in neuroscience and creative writing in 2018 from Western Washington University, and is now a graduate student in the MA Science Writing program at Johns Hopkins University. She writes stories about neuroscience, biology, and public health. Her essays and articles have appeared in Jeopardy Magazine and Leafly. When Hanna is not writing, she enjoys consuming other art forms, such as photography, poetry, creative nonfiction, and live music